Epharm Laboratories’ Post

Here is the 𝐟𝐢𝐟𝐭𝐡 𝐞𝐝𝐢𝐭𝐢𝐨𝐧 of "𝐓𝐡𝐞 𝐁𝐮𝐳𝐳" newsletter!! In this edition, you’ll find: * The 𝐥𝐚𝐭𝐞𝐬𝐭 𝐧𝐞𝐰𝐬 𝐚𝐧𝐝 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 in our industry * Exclusive 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐚𝐧𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 * Celebrations * 𝐌𝐨𝐧𝐭𝐡𝐥𝐲 𝐚𝐧𝐝 𝐐𝐮𝐚𝐫𝐭𝐞𝐫𝐥𝐲 award winners * And much more!! Our goal is to keep you informed, engaged, and connected. Enjoy reading 𝐓𝐇𝐄 𝐁𝐔𝐙𝐙. #Pharma #Prewellabs #Incepbio #TheBuzz

Here is the 𝐟𝐢𝐟𝐭𝐡 𝐞𝐝𝐢𝐭𝐢𝐨𝐧 of "𝐓𝐡𝐞 𝐁𝐮𝐳𝐳" newsletter!! In this edition, you’ll find: * The latest 𝐧𝐞𝐰𝐬 𝐚𝐧𝐝 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 in our industry * Exclusive 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐚𝐧𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 * Celebrations * 𝐌𝐨𝐧𝐭𝐡𝐥𝐲 𝐚𝐧𝐝 𝐐𝐮𝐚𝐫𝐭𝐞𝐫𝐥𝐲 award winners * And much more!! Our goal is to keep you informed, engaged, and connected. Enjoy reading 𝐓𝐇𝐄 𝐁𝐔𝐙𝐙! #pharma #incepbio #prewellabs #thebuzz

VARAHABHATLA N S SARMA talks about how the USFDA is schooling pharma companies on using QAMS for top-notch quality! ✅ Traceability is key to avoiding mistakes and ensuring the best standards! ✨ Watch the full episode now! Link: https://lnkd.in/gkMx7pdN #PharmaQuality #USFDA #PodcastKnowledge #TheGBShow #CXOJunction #pharma #healthcaresector

A great snapshot into last week's #MedComms Forum hosted by NetworkPharma Ltd and sponsored by aps Events & Media. It was wonderful to see so many faces (old and new). Here are some of my key personal highlights: Session 1 - Event Landscapes, Insights, and Demands 💻 Face-to-face engagement is important; however, virtual and hybrid meetings are often more inclusive for those unable to attend in-person. 🤝 Medical societies need to engage with new audiences and reformulate sponsorship policies to focus on partnerships. 🎯 The industry needs to focus on key impact indicators as well as key performance indicators to provide maximal benefit to society. Session 2 - Compliance, 2024 Code 📜 Navigating national codes can be challenging, with compliance barriers (and company risk tolerance) often hindering meaningful patient engagement. 🗞 The updated ABPI code of conduct is expected in the 4th quarter of 2024, with a 3-month transition period planned upon publication. Session 3 - Patient Inclusion 🎙 Meaningful patient engagement can be realised when patients are involved in the planning, delivery, evaluation, and leadership of scientific congresses. 🔗 Congress organisers should consider integrated patient tracks and accessibility when planning meetings to ensure maximal impact for everyone involved. 💼 Education, networking, and collaboration are key reasons why patients want to attend scientific congresses. #MedicalCommunications #MedicalAffairs #MedAffairs #Pharma #PatientEngagement #PatientInvolvement #PatientsInvolved #PatientAdvocacy #PatientsIncluded #IntegratedPatientEngagement

Softgel technology with lipid-based drug delivery systems, significantly boosts the bioavailability of new pharmaceutical molecules. Encapsulating active ingredients in a gelatin shell with lipid carriers improves solubility and absorption.

Listen to EQL's CEO Axel Schörling present the fourth quarter of 2023/24, a quarter of continued growth and profitability for the company, despite many challenges. Axel will also tell you about the projected sales growth for the coming year and the new products being launched. (length: 5 minutes) *English subtitles are available #generics #pharmaceutical #investorrelations #quarterlyreport

Register today for our upcoming webinar! https://buff.ly/3AmGuJs Learn how to develop control strategies in line with ICH M7 guidelines without expensive and time-consuming analytical testing. This webinar will show you how you can assess carryover risk for potentially mutagenic impurities (including nitrosamines) in your drug development workflow. The webinar will include the follow presentations: ☑️ Andrew Teasdale - ‘Industry perspective: Controlling potentially mutagenic impurities – Using calculations to support purge arguments under ICH M7’ ☑️ Emma Pye - ‘Purge Factors as part of M7 Assessment of mutagenic impurity risk – Using #Mirabilis to assist in control strategies.’ and conclude with a live Q&A #Pharma #Nitrosamines #ICHM7 #MutagenicImpurities

I am excited and thrilled to speak on this important topic comparing the various bioavailability enhancing technologies with case studies. Overlooking Softgel as a dosage form whether it is for DCS II or IV and considering it as a last resort instead of making it a first choice is proving costly both in terms of time and money especially with new treatment modalities like Protein degraders and other poorly bioavailable molecules. Please join us to see how we BUST various MYTHS with data/ facts on the MOST versatile dosage form ever, (that is Softgel)and see it for yourself to convince..

It's almost time for Asembia 2024! We are counting down until we get to join thousands of industry peers for Asembia's 20th Summit next month! #asembia24 #specialtypharmacy #pharmacy #pharma #lifesciences #marketaccess #healthsystems #improvingoutcomes

Last year was pharma’s second-hottest ever in terms of new active substances (NASs) introduced to the market. While the forecast for NAS launches is generally fair, there are a few clouds on the horizon in terms of a high Phase II failure rate and a small number of first-in-class drugs launched in 2023. Explore the detailed statistics on NASs in Citeline's latest infographic and delve deeper into the comprehensive report available here: https://ow.ly/ebRY50RmNFz #PharmaTrends #DrugDevelopment #BiopharmaInsights #PharmaIndustry #PharmaStatistics